Showing results (111-120 of 180) with videos related to
Sort By:
Pageof 18
Leukemia|May 24, 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Monika Engelhardt, Gordon Cook, et al.Blood|May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trialsCharlotte A Bradbury, Zoe Craig, Gordon Cook, et al.Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.European Journal of Haematology|January 13, 2026
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data AnalysisNoemi Puig, Xavier Leleu, Hans C Lee, et al.Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular RiskRuth M de Tute, Charlotte Pawlyn, David A Cairns, et al.European Journal of Haematology|December 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccinationClement Twumasi, Sally Moore, Ross Sadler, et al.The Lancet. Haematology|September 9, 2024
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trialGordon Cook, A John Ashcroft, Ethan Senior, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.Pageof 18